secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2026-08-11T12:01:29+00:00
Accession:  0001493152-26-036985
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IMUNON Q2 net loss $2.8M; OVATION 2 shows 14.7-month OS benefit, Phase 3 on track
--------------------------------------------------------------------------------

- Q2 2026 net loss $2.8M ($0.54/share) vs $2.7M ($2.15/share) in Q2 2025; H1 loss $7.1M ($1.38/share).
- Cash and equivalents $6.9M at June 30, 2026; operating cash burn $7.0M in H1 2026 vs $5.8M prior year.
- OVATION 2 final data: median OS 45.1 vs 30.4 months (14.7-month gain) for IMNN-001+SoC vs SoC alone.
- Phase 3 OVATION 3 enrollment exceeds forecasts; DMC recommended continuation; completion expected H1 2029.
- Phase 2 MRD data: MRD-positive 44% vs 67%, ctDNA clearance 87.5% vs 62.5%, NED 100% vs 56% for IMNN-001 vs control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/0001493152-26-036985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer